Jounce Therapeutics

Senior/Principal Scientist, Translational Pathology

Job ID
2021-1249
Category
Research & Development
Job Location
US-MA-Cambridge

Role / Responsibilities

Jounce Therapeutics is seeking an experienced translational scientist to join the Translational Pathology team and contribute to the development of novel cancer immunotherapies. The successful candidate will be responsible for managing multiple aspects of preclinical and clinical development of biomarker assays and applying histologic techniques and image analysis to better understand the tumor micro-environment. As part of a multi-disciplinary team, they will be expected to proactively interact with project teams and external collaborators to provide insights and brainstorm ideas on how histologic techniques can be applied to advance Jounce programs.

 

Responsibilities:

  • Contribute scientific and subject matter expertise to Jounce programs from early discovery to clinical stage.
  • Provide insights and support in histology, immunohistochemistry, RNA in situ hybridization and other tissue-based assays to programs.
  • Work cross-functionally with other Research functions to identify and establish assays and technologies to support mechanistic studies and biomarker validation.
  • Lead improvement of current processes withing the Pathology groups, and evaluate novel technologies and modalities with the potential to impact Jounce discovery platform and pipeline.
  • Manage and guide the development of SOPs for the central lab; manage the scientific review, QC and presentation of external vendor results. 
  • Write, update, and provide training on laboratory SOPs, provide input on SAP, and data transfer agreements and clinical study reports. 
  • Train and continuously develop scientists in the pathology group. 

Qualifications

  • Ph.D., M.D. or DVM in immunology, oncology, pathology or related field with a minimum of 3 years’ translational research experience in industry setting; or MS candidates with a minimum of 10 years’ translational research experience in industry setting and strong scientific background.
  • In depth knowledge of immunohistochemistry procedures  (tissue dissection, routine histology, immunohistochemistry, in-situ hybridization, image capture of fresh, frozen and paraffin-embedded tissues and cell lines) and ability to mentor and train junior associates on these.
  • Experience with the design, development and analysis of cellular, protein-based, and/or molecular biomarkers.
  • Good understanding of clinical drug development strategies and quality-related requirements in drug development.
  • Experience coordinating third party outsourced assays, standards, interpretation, and reporting; experience with clinical assay transfer is a plus.
  • Experience in immuno-oncology, biologics, molecular biology and cell biology preferred.
  • Toxicologic  pathology assessment and biomarker plan development experience is a plus.
  • Demonstrate excellent interpersonal, verbal and written communication skills.
  • Excel in cross-functional, collaborative and fast-paced settings.

Statement

Jounce Therapeutics is an equal opportunity employer and does not discriminate in its employment decisions on the basis of race, color, national origin, age, physical or mental disability, marital status, religion, creed, sex, or political beliefs.  We offer a competitive salary and benefits package. All applicants should be legally entitled to work for any employer in the U.S.  

Company Summary

Jounce Therapeutics, Inc. is a clinical-stage immunotherapy company dedicated to transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long-lasting benefits to patients through a biomarker-driven approach. Jounce currently has multiple development stage programs ongoing while simultaneously advancing additional early-stage assets from its robust discovery engine based on its Translational Science Platform. Jounce’s highest priority program, JTX-8064, is a LILRB2 (ILT4) receptor antagonist shown to reprogram immune-suppressive tumor associated macrophages to an anti-tumor state in preclinical studies. A Phase 1 clinical trial, named INNATE, for JTX-8064 as a monotherapy and in combination with JTX-4014, Jounce’s internal PD-1 inhibitor, or pembrolizumab is currently enrolling patients with advanced solid tumors. Jounce’s most advanced product candidate, vopratelimab, is a monoclonal antibody that binds to and activates ICOS, and is currently being studied in the SELECT Phase 2 trial. JTX-4014 is a PD-1 inhibitor intended for combination use in the INNATE and SELECT trials and with Jounce’s broader pipeline. Additionally, Jounce exclusively licensed worldwide rights to JTX-1811, a monoclonal antibody targeting CCR8 and designed to selectively deplete T regulatory cells in the tumor microenvironment, to Gilead Sciences, Inc. For more information, please visit www.jouncetx.com. 

Options

Sorry the Share function is not working properly at this moment. Please refresh the page and try again later.
Share on your newsfeed